Your browser doesn't support javascript.
loading
Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma.
Wen, Feng; Zheng, Hanrui; Wu, Yifan; Wheeler, John; Zeng, Xiaoxi; Fu, Ping; Li, Qiu.
Afiliação
  • Wen F; Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, China.
  • Zheng H; West China Biostatistics and Cost-Benefit Analysis Center, Sichuan University, China.
  • Wu Y; West China Biostatistics and Cost-Benefit Analysis Center, Sichuan University, China.
  • Wheeler J; Department of Clinical Pharmacy, West China Hospital, Sichuan University, China.
  • Zeng X; School of Public Health, University of Michigan, Ann Arbor, Michigan 48109, USA.
  • Fu P; School of Public Health, University of Michigan, Ann Arbor, Michigan 48109, USA.
  • Li Q; West China Biostatistics and Cost-Benefit Analysis Center, Sichuan University, China.
Sci Rep ; 6: 36060, 2016 11 08.
Article em En | MEDLINE | ID: mdl-27824060
No standard treatment has been accepted widely for the first-/second-line therapy for advanced gastric cancer (AGC). The current study aimed to determine a preferred strategy between FOLFIRI (fluorouracil, leucovorin, and irinotecan) and ECX (epirubicin, cisplatin,and capecitabine) for AGC from the cost-effectiveness perspective. According to a French intergroup study, two groups (ECX arm and FOLFIRI arm) and three health states (progression-free survival (PFS), progressive disease (PD) and death) were analyzed in the current Markov model. All the medical costs were calculated from a Chinese societal perspective. Although FOLFIRI was an acceptable first-line therapy in the treatment of AGC with a better time-to treatment failure (TTF) compared to ECX, ECX arm (ECX followed by FOLFIRI) gained 0.08 quality-adjusted life months (QALMs) more effectiveness benefit compared with FOLFIRI arm (FOLFIRI followed by ECX). Additionally, a lower cost was found in ECX arm ($23,813.13 versus $24,983.70). Hence, the strategy of FOLFIRI arm is dominated by ECX arm ($4,125.8 per QALM in FOLIRI arm; $3,879.724 per QALM in ECX arm). ECX followed by FOLFIRI was a preferred strategy with more effectiveness and lower cost compared with FOLFIRI followed by ECX for the treatment of AGC.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Adenocarcinoma / Análise Custo-Benefício / Tratamento Farmacológico / Antineoplásicos Tipo de estudo: Health_economic_evaluation Aspecto: Patient_preference Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Sci Rep Ano de publicação: 2016 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Adenocarcinoma / Análise Custo-Benefício / Tratamento Farmacológico / Antineoplásicos Tipo de estudo: Health_economic_evaluation Aspecto: Patient_preference Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Sci Rep Ano de publicação: 2016 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido